Login is disabled for site maintenance during the period: 13:00 - 14:00 GMT

Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The 1st Immunotherapy of Cancer Conference (ITOC)

1st Immunotherapy of Cancer Conference (ITOC 1)

12 - 14 Mar 2014

Published: 25 Mar 2014

Views: 3136

Rating:

Save

Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria

Prof Heinz Zwierina, chair of ITOC 2014, talks to ecancertv about the meeting's key points and future.

Immunotherapy for cancer has taken huge leaps forwards in the last couple of years, and progress is only accelerating, so ITOC is set to become an important fixture.

Related Videos

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India

Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

More from ecancer